Drug Profile
Research programme: neurodegenerative disorders therapeutics - Galantos Pharma
Alternative Names: Antidementia drugs programme - Galantos Pharma; Antidementive drugs programme - Galantos PharmaLatest Information Update: 29 Nov 2012
Price :
$50
*
At a glance
- Originator Galantos Pharma
- Class
- Mechanism of Action Cholinergic receptor modulators; Cholinesterase inhibitors; Nicotinic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 15 May 2012 Discontinued - Preclinical for Alzheimer's disease in Germany (unspecified route)
- 15 May 2012 Discontinued - Preclinical for Neurodegenerative disorders in Germany (unspecified route)
- 29 Aug 2007 Galantos Pharma is seeking collaboration opportunities for this programme (http://www.galantos.com)